[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. / Erichsen, Kamille Dumong; Johnbeck, Camilla Bardram; Björkling, Fredrik; Madsen, Jacob; Bzorek, Michael; Jensen, Peter Buhl; Højgaard, Liselotte; Sehested, Maxwell; Kjær, Andreas; Jensen, Mette Munk.

In: P L o S One, Vol. 8, No. 1, e53410, 2013, p. 1-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Erichsen, KD, Johnbeck, CB, Björkling, F, Madsen, J, Bzorek, M, Jensen, PB, Højgaard, L, Sehested, M, Kjær, A & Jensen, MM 2013, '[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts', P L o S One, vol. 8, no. 1, e53410, pp. 1-8. https://doi.org/10.1371/journal.pone.0053410

APA

Erichsen, K. D., Johnbeck, C. B., Björkling, F., Madsen, J., Bzorek, M., Jensen, P. B., Højgaard, L., Sehested, M., Kjær, A., & Jensen, M. M. (2013). [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. P L o S One, 8(1), 1-8. [e53410]. https://doi.org/10.1371/journal.pone.0053410

Vancouver

Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB et al. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. P L o S One. 2013;8(1):1-8. e53410. https://doi.org/10.1371/journal.pone.0053410

Author

Erichsen, Kamille Dumong ; Johnbeck, Camilla Bardram ; Björkling, Fredrik ; Madsen, Jacob ; Bzorek, Michael ; Jensen, Peter Buhl ; Højgaard, Liselotte ; Sehested, Maxwell ; Kjær, Andreas ; Jensen, Mette Munk. / [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. In: P L o S One. 2013 ; Vol. 8, No. 1. pp. 1-8.

Bibtex

@article{b1ca91311b3640d28308e9c06134f07c,
title = "[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts",
abstract = "APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.",
author = "Erichsen, {Kamille Dumong} and Johnbeck, {Camilla Bardram} and Fredrik Bj{\"o}rkling and Jacob Madsen and Michael Bzorek and Jensen, {Peter Buhl} and Liselotte H{\o}jgaard and Maxwell Sehested and Andreas Kj{\ae}r and Jensen, {Mette Munk}",
year = "2013",
doi = "10.1371/journal.pone.0053410",
language = "English",
volume = "8",
pages = "1--8",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

RIS

TY - JOUR

T1 - [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

AU - Erichsen, Kamille Dumong

AU - Johnbeck, Camilla Bardram

AU - Björkling, Fredrik

AU - Madsen, Jacob

AU - Bzorek, Michael

AU - Jensen, Peter Buhl

AU - Højgaard, Liselotte

AU - Sehested, Maxwell

AU - Kjær, Andreas

AU - Jensen, Mette Munk

PY - 2013

Y1 - 2013

N2 - APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

AB - APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

U2 - 10.1371/journal.pone.0053410

DO - 10.1371/journal.pone.0053410

M3 - Journal article

C2 - 23308217

VL - 8

SP - 1

EP - 8

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

M1 - e53410

ER -

ID: 45864162